Provided by Tiger Trade Technology Pte. Ltd.

Vivos Therapeutics

1.19
+0.05004.39%
Pre-market: 1.200.0073+0.61%08:00 EDT
Volume:255.23K
Turnover:321.54K
Market Cap:12.46M
PE:-0.62
High:1.36
Open:1.13
Low:1.10
Close:1.14
52wk High:7.95
52wk Low:1.09
Shares:10.47M
Float Shares:8.39M
Volume Ratio:2.55
T/O Rate:3.04%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.9054
EPS(LYR):-2.2184
ROE:-335.45%
ROA:-49.76%
PB:4.92
PE(LYR):-0.54

Loading ...

Alliance Global Partners Sticks to Its Hold Rating for Vivos Therapeutics (VVOS)

TIPRANKS
·
Jan 09

Vivos Therapeutics Opens New Sleep Center in Auburn Hills, Michigan

Reuters
·
Dec 16, 2025

Vivos Therapeutics Executives Join Water Tower Research Online Fireside Chat

Reuters
·
Dec 16, 2025

Vivos Therapeutics Secures $2.1 Million Unsecured Loan from Avondale Capital

Reuters
·
Dec 06, 2025

Vivos Therapeutics Is Maintained at Buy by Ascendiant Capital

Dow Jones
·
Dec 03, 2025

Vivos Therapeutics Reports Strong Q3 Growth Amid Challenges

TIPRANKS
·
Nov 22, 2025

Vivos Therapeutics Reports Revenue Growth Amid Strategic Shift

TIPRANKS
·
Nov 20, 2025

Vivos Therapeutics Reports 78% Sequential Revenue Growth in Third Quarter 2025

Reuters
·
Nov 20, 2025

Vivos Therapeutics Q3 revenue rises, helped by SCN acquisition

Reuters
·
Nov 20, 2025

Vivos Therapeutics reports Q3 EPS (49c), consensus (51c)

TIPRANKS
·
Nov 20, 2025

BRIEF-Vivos Therapeutics Q3 Net Income USD -5.4 Million

Reuters
·
Nov 20, 2025

Vivos Therapeutics Inc - Qtrly Net Loss per Share Basic and Diluted $0.49

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Q3 Gross Profit USD 3.937 Million

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Inc - Revenue $6.8 Mln in Q3 2025

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Reports Significant Revenue Growth During the Third Quarter 2025

THOMSON REUTERS
·
Nov 20, 2025

Vivos Therapeutics Q3 EPS $(0.49) Misses $(0.41) Estimate, Sales $6.783M Beat $4.686M Estimate

Benzinga
·
Nov 20, 2025

Vivos Therapeutics Schedules Release of Third Quarter 2025 Financial Results and Conference Call

GlobeNewswire
·
Nov 19, 2025

Vivos Therapeutics Initiated at Buy by HC Wainwright & Co.

Dow Jones
·
Nov 17, 2025

Vivos Therapeutics initiated with a Buy at H.C. Wainwright

TIPRANKS
·
Nov 17, 2025

Vivos Therapeutics, Inc. : H.c. Wainwright Initiates Coverage With Buy Rating and Target Price $7

THOMSON REUTERS
·
Nov 17, 2025